Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals

02:40 EDT 18 Jul 2019 | FinanzNachrichten

- Payment follows IND approval from US FDA for first-in-human clinical trial of APP13007 for post-operative inflammation of the eye - Sosei Heptares remains eligible to receive undisclosed milesto...

More From BioPortfolio on "Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals"